KR102974656B1 - 항체를 사용한 암 치료 - Google Patents

항체를 사용한 암 치료

Info

Publication number
KR102974656B1
KR102974656B1 KR1020217007105A KR20217007105A KR102974656B1 KR 102974656 B1 KR102974656 B1 KR 102974656B1 KR 1020217007105 A KR1020217007105 A KR 1020217007105A KR 20217007105 A KR20217007105 A KR 20217007105A KR 102974656 B1 KR102974656 B1 KR 102974656B1
Authority
KR
South Korea
Prior art keywords
ser
val
cancer
leu
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217007105A
Other languages
English (en)
Korean (ko)
Other versions
KR20210088523A (ko
Inventor
크리스토퍼 배리 우드
티나 씨. 플라타우
피오나 뎀시
스콧 크라이튼
Original Assignee
메드어넥스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메드어넥스 리미티드 filed Critical 메드어넥스 리미티드
Publication of KR20210088523A publication Critical patent/KR20210088523A/ko
Application granted granted Critical
Publication of KR102974656B1 publication Critical patent/KR102974656B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217007105A 2018-08-10 2019-08-12 항체를 사용한 암 치료 Active KR102974656B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1813137.5A GB201813137D0 (en) 2018-08-10 2018-08-10 Cancer treatment with an antibody
GB1813137.5 2018-08-10
PCT/EP2019/071627 WO2020030827A1 (en) 2018-08-10 2019-08-12 Cancer treatment with an antibody

Publications (2)

Publication Number Publication Date
KR20210088523A KR20210088523A (ko) 2021-07-14
KR102974656B1 true KR102974656B1 (ko) 2026-06-08

Family

ID=63667034

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007105A Active KR102974656B1 (ko) 2018-08-10 2019-08-12 항체를 사용한 암 치료

Country Status (12)

Country Link
US (1) US11858982B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833404A1 (cg-RX-API-DMAC7.html)
JP (2) JP7428696B2 (cg-RX-API-DMAC7.html)
KR (1) KR102974656B1 (cg-RX-API-DMAC7.html)
CN (1) CN112770786B (cg-RX-API-DMAC7.html)
AU (1) AU2019319092B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002435A2 (cg-RX-API-DMAC7.html)
GB (1) GB201813137D0 (cg-RX-API-DMAC7.html)
IL (1) IL280421B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021001604A (cg-RX-API-DMAC7.html)
TW (1) TW202014437A (cg-RX-API-DMAC7.html)
WO (1) WO2020030827A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023089150A1 (en) 2021-11-18 2023-05-25 Medannex Ltd. Combination therapy for cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534914A (ja) 2010-06-09 2013-09-09 クイーン マリー アンド ウエストフィールド カレッジ、ユニバーシティ オブ ロンドン アネキシン１抗体
US20150086553A1 (en) 2013-09-10 2015-03-26 Samsung Electronics Co., Ltd. Polypeptide binding to annexin a1 and use thereof
WO2018146230A1 (en) 2017-02-08 2018-08-16 Medannex Ltd. Anti human annexin a1 antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219299A1 (en) 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
WO2004055519A2 (en) 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
WO2005027965A1 (en) 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
CA2572451C (en) 2004-06-02 2016-05-10 Sidney Kimmel Cancer Center Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
CN100571785C (zh) * 2006-09-06 2009-12-23 中国医学科学院北京协和医院 Annexin A3与癌症的铂类化疗药物耐药性的相关性
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
CN102898527B (zh) 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
WO2015039175A1 (en) 2013-09-18 2015-03-26 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用
WO2019222618A1 (en) 2018-05-17 2019-11-21 The Trustees Of Columbia University In The City Of New York Methods for treating, preventing and detecting the prognosis of colorectal cancer
JP2021533163A (ja) 2018-08-07 2021-12-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. アネキシンａ１を介した心血管石灰化の阻害に関する方法および組成物
WO2020112129A1 (en) 2018-11-30 2020-06-04 Prism | Proteogenomics Research Institute For Systems Medicine Enhanced targeted delivery of therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534914A (ja) 2010-06-09 2013-09-09 クイーン マリー アンド ウエストフィールド カレッジ、ユニバーシティ オブ ロンドン アネキシン１抗体
US20150086553A1 (en) 2013-09-10 2015-03-26 Samsung Electronics Co., Ltd. Polypeptide binding to annexin a1 and use thereof
WO2018146230A1 (en) 2017-02-08 2018-08-16 Medannex Ltd. Anti human annexin a1 antibody

Also Published As

Publication number Publication date
US20210238269A1 (en) 2021-08-05
CA3107674A1 (en) 2020-02-13
JP2021534121A (ja) 2021-12-09
JP7728035B2 (ja) 2025-08-22
IL280421B1 (en) 2024-02-01
IL280421B2 (en) 2024-06-01
KR20210088523A (ko) 2021-07-14
CN112770786A (zh) 2021-05-07
JP2024041851A (ja) 2024-03-27
TW202014437A (zh) 2020-04-16
AU2019319092B2 (en) 2026-04-02
IL280421A (en) 2021-03-25
AU2019319092A1 (en) 2021-03-18
MX2021001604A (es) 2021-04-19
EP3833404A1 (en) 2021-06-16
WO2020030827A1 (en) 2020-02-13
GB201813137D0 (en) 2018-09-26
US11858982B2 (en) 2024-01-02
BR112021002435A2 (pt) 2021-05-04
JP7428696B2 (ja) 2024-02-06
CN112770786B (zh) 2023-10-27

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000